CN106456580B - 作为蛋白质脱乙酰酶抑制剂和蛋白质脱乙酰酶-蛋白质激酶双重抑制剂的杂环异羟肟酸及其使用方法 - Google Patents

作为蛋白质脱乙酰酶抑制剂和蛋白质脱乙酰酶-蛋白质激酶双重抑制剂的杂环异羟肟酸及其使用方法 Download PDF

Info

Publication number
CN106456580B
CN106456580B CN201580024748.8A CN201580024748A CN106456580B CN 106456580 B CN106456580 B CN 106456580B CN 201580024748 A CN201580024748 A CN 201580024748A CN 106456580 B CN106456580 B CN 106456580B
Authority
CN
China
Prior art keywords
amino
purin
phenoxy
cyclohexylamino
pyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580024748.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN106456580A (zh
Inventor
刘学东
张甘
丹尼尔·全丰·陈
安东尼·D·皮斯寇皮欧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colorado State University Board Of Incorporations
Original Assignee
Colorado State University Board Of Incorporations
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colorado State University Board Of Incorporations filed Critical Colorado State University Board Of Incorporations
Publication of CN106456580A publication Critical patent/CN106456580A/zh
Application granted granted Critical
Publication of CN106456580B publication Critical patent/CN106456580B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201580024748.8A 2014-05-14 2015-05-14 作为蛋白质脱乙酰酶抑制剂和蛋白质脱乙酰酶-蛋白质激酶双重抑制剂的杂环异羟肟酸及其使用方法 Active CN106456580B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461996702P 2014-05-14 2014-05-14
US201461996691P 2014-05-14 2014-05-14
US61/996,691 2014-05-14
US61/996,702 2014-05-14
PCT/US2015/030842 WO2015175813A1 (en) 2014-05-14 2015-05-14 Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
CN106456580A CN106456580A (zh) 2017-02-22
CN106456580B true CN106456580B (zh) 2020-09-04

Family

ID=54480695

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580024748.8A Active CN106456580B (zh) 2014-05-14 2015-05-14 作为蛋白质脱乙酰酶抑制剂和蛋白质脱乙酰酶-蛋白质激酶双重抑制剂的杂环异羟肟酸及其使用方法

Country Status (11)

Country Link
US (3) US9840520B2 (https=)
EP (1) EP3142652B1 (https=)
JP (1) JP6803235B2 (https=)
KR (1) KR20170003688A (https=)
CN (1) CN106456580B (https=)
BR (1) BR112016026518A2 (https=)
CA (1) CA2949163A1 (https=)
MX (1) MX2016014911A (https=)
RU (1) RU2016148863A (https=)
TW (1) TW201625620A (https=)
WO (1) WO2015175813A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014308616B2 (en) 2013-08-23 2018-12-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
JP6803235B2 (ja) 2014-05-14 2020-12-23 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ タンパク質脱アセチル化酵素阻害剤およびタンパク質脱アセチル化酵素−タンパク質キナーゼ二重阻害剤としての複素環式ヒドロキサム酸ならびにその使用方法
EP3233860B1 (en) * 2014-12-15 2020-01-29 Univerzita Palackého V Olomouci Substituted 6-anilino-9-heterocyclylpurine derivatives for inhibition of plant stress
CN107613769A (zh) * 2015-02-17 2018-01-19 润新生物公司 某些化学实体、组合物和方法
CN106831780A (zh) * 2015-12-03 2017-06-13 南开大学 具有cdk4/6和hdac抑制活性的新型杂环衍生物
CN109843858B (zh) 2016-08-15 2023-05-05 润新生物公司 某些化学实体、组合物及方法
MA46620A (fr) * 2016-10-28 2021-05-26 Bristol Myers Squibb Co Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha
IT201700041723A1 (it) * 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6
CN107513064B (zh) * 2017-09-27 2019-07-09 南昌大学 一种嘌呤异羟肟酸衍生物及其制备方法和应用
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
KR102847312B1 (ko) * 2021-12-30 2025-08-19 한국화학연구원 피라졸로피리미딘 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
JP7807025B2 (ja) * 2021-12-30 2026-01-27 コリア リサーチ インスティチュート オブ ケミカル テクノロジー ピラゾロピリミジン誘導体及びこれを有効成分として含有する抗癌用薬学的組成物
CN114685507B (zh) * 2022-04-06 2024-01-12 山东大学 嘌呤胺衍生物类cdk2抑制剂及其制备方法和应用
KR102792443B1 (ko) * 2022-05-13 2025-04-08 서울대학교산학협력단 Cdk를 저해하는 신규 피롤로피리미디논 카복사미드 화합물, 이의 입체이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1279669A (zh) * 1997-11-14 2001-01-10 G·D·瑟尔公司 芳族砜异羟肟酸金属蛋白酶抑制剂
KR20140118575A (ko) * 2013-03-29 2014-10-08 한미약품 주식회사 신규한 하이드록사메이트 유도체

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380258B2 (en) 1997-03-04 2002-04-30 G. D. Searle, L.L.C. Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US20020049237A1 (en) 1998-03-17 2002-04-25 Newton Roger Schofield Statin-MMP inhibitor combinations
US6642255B2 (en) 2001-01-11 2003-11-04 Bristol-Myers Squibb Pharma Company 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha
JPWO2002074298A1 (ja) * 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
AU2003900608A0 (en) * 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
SI1611088T1 (sl) * 2003-04-07 2009-12-31 Pharmacyclics Inc Hidroksamati kot terapevtska sredstva
EP1648867B1 (en) 2003-07-17 2013-09-04 Plexxikon Inc. Ppar active compounds
US7834011B2 (en) * 2006-01-19 2010-11-16 Janssen Pharmaceutica N.V. Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
US8962825B2 (en) 2006-10-30 2015-02-24 Glaxosmithkline Intellectual Property Development Limited Hydroxamates as inhibitors of histone deacetylase
US20100298557A1 (en) * 2006-12-28 2010-11-25 Taisho Pharmaceutical Co., Ltd Pyrazolopyrimidine compound
WO2009036066A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
KR101168801B1 (ko) * 2009-03-27 2012-07-25 주식회사종근당 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
TWI600638B (zh) * 2010-01-22 2017-10-01 艾斯特隆製藥公司 作爲蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法
WO2011146591A1 (en) * 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012170827A2 (en) * 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
WO2013041407A1 (en) * 2011-09-19 2013-03-28 Cellzome Ag Hydroxamic acids as hdac6 inhibitors
JP6803235B2 (ja) 2014-05-14 2020-12-23 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ タンパク質脱アセチル化酵素阻害剤およびタンパク質脱アセチル化酵素−タンパク質キナーゼ二重阻害剤としての複素環式ヒドロキサム酸ならびにその使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1279669A (zh) * 1997-11-14 2001-01-10 G·D·瑟尔公司 芳族砜异羟肟酸金属蛋白酶抑制剂
KR20140118575A (ko) * 2013-03-29 2014-10-08 한미약품 주식회사 신규한 하이드록사메이트 유도체

Also Published As

Publication number Publication date
JP2017515848A (ja) 2017-06-15
US10508122B2 (en) 2019-12-17
CN106456580A (zh) 2017-02-22
BR112016026518A2 (pt) 2017-08-15
RU2016148863A3 (https=) 2018-12-17
RU2016148863A (ru) 2018-06-18
WO2015175813A1 (en) 2015-11-19
US20170081343A1 (en) 2017-03-23
USRE47690E1 (en) 2019-11-05
MX2016014911A (es) 2017-04-06
EP3142652B1 (en) 2021-08-25
US20180044352A1 (en) 2018-02-15
US9840520B2 (en) 2017-12-12
JP6803235B2 (ja) 2020-12-23
KR20170003688A (ko) 2017-01-09
CA2949163A1 (en) 2015-11-19
EP3142652A4 (en) 2017-11-29
EP3142652A1 (en) 2017-03-22
TW201625620A (zh) 2016-07-16

Similar Documents

Publication Publication Date Title
CN106456580B (zh) 作为蛋白质脱乙酰酶抑制剂和蛋白质脱乙酰酶-蛋白质激酶双重抑制剂的杂环异羟肟酸及其使用方法
US12234235B2 (en) Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CN111278815B (zh) 戊二酰亚胺
ES2896502T3 (es) Formas cristalinas de ácido 4-(1-(1,1-di(piridin-2-il) etil)-6-(3,5-dimetilisoxazol-4-il)-1H-pirrolo[3,2-b]piridin-3- il)benzoico que inhiben el bromodominio
AU2017258187B2 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
CA2917364C (en) Heterocyclic compounds and uses thereof
RU2638932C2 (ru) Индазольные ингибиторы сигнального пути wnt и их терапевтические применения
JP6035423B2 (ja) 新規な縮合ピリミジン化合物又はその塩
TW202144345A (zh) Ｋｒａｓ突變蛋白抑制劑
CN102014914A (zh) 3h-[1,2,3]三唑并[4,5-d]嘧啶化合物、其作为mtor激酶和pi3激酶抑制剂的用途、以及它们的合成
CN102952118B (zh) 聚（adp-核糖）聚合酶抑制剂、制备方法及其用途
CA3240011A1 (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
CN113747894B (zh) 成纤维细胞生长因子受体2(fgfr2)的降解剂
WO2020147097A1 (zh) 一种新型的脂质体激酶抑制剂
HK1229722B (zh) 作为蛋白质脱乙酰酶抑制剂和蛋白质脱乙酰酶-蛋白质激酶双重抑制剂的杂环异羟肟酸及其使用方法
CN111138426A (zh) 吲唑类激酶抑制剂及其用途
HK1229722A1 (en) Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1229722

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant